Lyell Immunopharma CMO sells $3,641 in shares for tax withholding

Chief Medical Officer Jarrad Mattieu Aguirre of Lyell Immunopharma sold 422 shares of the company's stock on October 12, 2026, in a transaction valued at $3,641. The shares were sold at prices between $8.54 and $8.63 each, as part of an automatic process to meet tax withholding duties resulting from the settlement of vested restricted stock units.

Since the transaction, the stock price has dropped to $7.51, hovering close to its 52-week low of $7.39. Analysts at InvestingPro see Lyell Immunopharma as undervalued at this time, with the stock down 68% over the past six months. Currently, Mr. Aguirre still owns 19,857 shares of the company. Additionally, Lyell Immunopharma recently reported its Q2 2026 earnings and outlined its future milestones.

The company has recently transferred LYL273 to LyFE following an FDA review of its enhanced manufacturing process and updated analytical methods. Lyell Immunopharma now anticipates forthcoming Phase 1/2 data in later-stage or later relapsed/refractory metastatic colorectal cancer, with an expected end-of-Phase 1 meeting in 2027.

Analyst firms H.C. Wainwright and Citizens have both issued Buy ratings for Lyell Immunopharma, with price targets of $45.00 and $34.00, respectively. Stifel Securities has also initiated coverage on the company with a Buy rating and price targets of $36.00 and $44.00, highlighting the potential of its CAR T-cell therapy, Ronde-cel, and Lyell's oncology efforts in clinical development.